Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction
Joi Suzuki Ninomoto, Ahmad Mokatrin, Taisei Kinoshita et al. · Hematology · 2020
Background: Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase (BTK), is approved in the US and EU for the treatment of various B-cell malignancies. In clinical studies, BTK inhibitors have been associated with increased bleeding risk, which may result from BTK inhibition in platelets.Methods: To better understand the mechanism of ibrutinib in bleeding events, we isolated platelet-rich plasma from healthy donors (n = 8) and donors with conditions associated with impaired platelet function or with potentially increased bleeding risk (on hemodialysis, taking aspirin, or taking warfarin; n = 8 each cohort) and used light transmission aggregometry to assess platelet aggregation in vitro after exposure to escalating concentrations of ibrutinib, spanning and exceeding the pharmacologic range of clinical exposure.Results: Platelet aggregation was induced by agonists of 5 major platelet receptors: adenosine diphosphate (ADP), thrombin receptor-activating peptide 6 (TRAP6), ristocetin, collagen, or arachidonic acid (AA). Platelet aggregation induced by ADP, TRAP6, ristocetin, and AA was not meaningfully inhibited by the maximal concentrations of ibrutinib (10 µM). In contrast, collagen-induced platelet aggregation was dose-dependently inhibited by ibrutinib in all donor cohorts (maximum aggregation % with 10 μM ibrutinib, −64% to −83% of agonist activity compared to control agonist samples but without ibrutinib).Conclusion: These results confirm prior reports and support a mechanistic role for the inhibition of collagen-induced platelet aggregation in bleeding events among susceptible individuals receiving ibrutinib therapy.
Cited by 15 works. doi:10.1080/16078454.2020.1730080 Open-access PDF
Authors
- Joi Suzuki Ninomoto
- Ahmad Mokatrin
- Taisei Kinoshita
- Carol Marimpietri
- Terrance D. Barrett
- Betty Y Chang
- Juthamas Sukbuntherng
- Danelle Frances James
- Mark Andrew Crowther
References
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
- Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
- A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen
- Ibrutinib in Relapsed Chronic Lymphocytic Leukemia